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Background
• Across Europe, the clinical and economic burden of advanced non-small cell lung cancer (aNSCLC) is high.
• Approximately 20% of cancer mortality in European men and women is due to lung cancer; the most common lung cancer type is non-small cell lung cancer (NSCLC) which accounts for approximately 85% of all lung cancer diagnoses [1] .
• Little is known about the real-world treatment, as well as cost and economic burden of aNSCLC in Europe.
• The Leading the Evaluation of Non-squamous and Squamous NSCLC study (LENS) was a real-world study that aimed to systematically document healthcare resource utilization (HCRU), and estimate costs for patients with aNSCLC treated with 2 or more lines of therapy in Europe.
Results
Patient and Disease Characteristics
• Charts for 835 patients (non-squamous, n = 418; squamous, n = 417) were evaluated, with a mean followup time of 20.7 months (range 2.8-57.1 months); 76.3% of identified patients were followed through death.
• Median age was 65 years; 85.0% of patients were categorized as ever smokes and 39.8% were current smokers.
• In general, patient characteristics were similar across the countries with the exception of a significantly, greater than 10.0% difference (p<0.05) across countries in smoking history, alcohol abuse dependency history, presence of and number of metastatic sites and ECOG performance status at baseline (Table 2) .
Conclusions
• The large number and geographic distribution of physicians participating in this study provides a rich, detailed dataset for hypothesis generation.
• Within this population of patients receiving 2L+ systemic therapy who were being treated by primarily hospitalbased oncologist, costs and resource use for aNSCLC patients receiving 2L+ are substantial.
• Treatment was the primary aNSCLC-related cost driver independent of country or histology.
-This study focuses on 2L+ patients, who have a longer experience with systemic treatment than the overall aNSCLC patient population, some of whom do not receive any systemic treatment. Therefore, the importance of systemic treatment costs as a fraction of the total in this study is specific to 2L patients and not representative of the average aNSCLC patient. -The study design is less likely to have led to omission of systemic treatment than other types of care delivered outside of the oncology/pulmonology practice, perhaps overstating the role of costs of systemic treatment as a % of the total.
• Total aNSCLC-related costs were lower for patients with squamous than non-squamous cell histology. Histologybased differences in treatment costs were driven by lower systemic use in patients with squamous cell histology potentially due to the availability of fewer treatment options.
• Considering the limited efficacy and high toxicity of existing treatments for aNSCLC, the cost effectiveness of real-world treatments for aNSCLC needs further exploration. History of smoking (current or ever)
710 (85) 
* Double counting possible Grade 0 "Fully active, able to carry on all pre-disease performance without restriction" to 5 "Dead" 
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Results, cont.
Healthcare Resource Utilization and Costs by Country
• By cohort definition, 100% of patients had 1L and 2L systemic therapies. Of these, 12.5% had 3L treatment and 2.2% had 4L systemic therapies, listed in Figure 1 . • 7.5% of patients had an ER visit; 63.5% of ER visits resulted in hospitalization (Table 3 ). • 11.9% of patients had an aNSCLC-related hospitalization. The average length of hospital stay ranged from 9.3 days in Spain to 12.8 days in France.
• Surgical procedures were performed on less than 5% of patients; diagnostic procedures performed on almost all patients with bronchoscopy, chest radiograph, CT scan, and needle aspiration core biopsy most frequently performed.
• Ancillary care services were more commonly utilized by patients in Italy and Spain than France and Germany.
• The majority of patients (68.3%) underwent biomarker testing.
• As per the inclusion criteria, all patients received systematic therapy for first and second line of therapy; 16.8% of patients received radiotherapy and 27.9% received supplemental therapies.
• Estimated per-patient lifetime aNSCLC-attributable costs differed significantly across countries (Figure 1 ). • Costs were driven by drug treatment costs; total mean drug treatment costs including administration were €50,737 ranging from €32,299 in Italy to €62,841 in Germany.
• Mean costs of drug treatment were higher in Germany than elsewhere, as median time until treatment discontinuation was 10-75 days longer for second line of therapy and beyond. The use and costs of radiotherapy were higher in France than elsewhere. Spanish patients received more supplemental therapies
Healthcare Resource Utilization and Costs by Histology
• Total treatment costs were lower for patients with squamous compared to non-squamous NSCLC.
• Estimated per-patient lifetime aNSCLC-attributable costs were €46,477 for squamous and €88,628 for nonsquamous cell cancer (Figure 2 ). • Costs were driven by drug treatment costs; total mean drug treatment costs including administration were €36,300 for squamous cell and €76,837 for nonsquamous cell cancer. [2, 3] Costs vary [4] Costs vary [5] Costs vary [6] Lab tests, imaging and mutation testing € 300 [20] € 300 [20] € 300 [20] € 300 [20] 
